Kymera Therapeutics Q2 2025 Earnings Call Transcript

Quartr
Provided by Quartr
August 11, 2025

Key Takeaways

  • Positive Sentiment: In healthy volunteers, the oral STAT6 degrader KT-621 achieved >95% target protein degradation at low doses and showed a safety profile indistinguishable from placebo, de-risking its pathway.
  • Positive Sentiment: The Phase 1b BROADEN trial in moderate to severe atopic dermatitis enrolled swiftly across two dose cohorts, and Chimera selected three doses for Phase 2b AD and asthma studies, with results due in Q4.
  • Positive Sentiment: The oral IRF5 degrader program (KT-579) is completing IND-enabling studies, targeting a key transcription factor in autoimmune diseases, and is on track for a Phase I start in early 2026.
  • Positive Sentiment: Under collaborations, Chimera received an $85 million upfront from Gilead for a CDK2 molecular glue degrader and Sanofi opted into the IRAK4 program, together offering up to ~$1.7 billion in milestones plus tiered royalties.
  • Positive Sentiment: Following a $250 million follow-on equity raise and Gilead upfront payment, Chimera ended Q2 with ~$1 billion in cash, extending its funding runway into 2028.
AI Generated. May Contain Errors.
Earnings Conference Call
Kymera Therapeutics Q2 2025
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

Good day everyone. My name is Olivia and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics second quarter twenty twenty five results call. All lines have been placed on mute to prevent any background noise. After the speakers remarks, there will be a question and answer session.

Operator

If you would like to ask a question during this time and if you have joined via the webinar, please use the raise hand icon which can be found at the bottom of your webinar application. If you have joined via phone, please dial 9 on your keypad to raise your hand. At this time, I would like to turn the call over to Bruce Jacobs, chief financial officer.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

Good morning. I'm Bruce Jacobs, and I'm kicking off this in place of Justine Konasberg, our head of IR, who is out today. Joining me this morning are Nella Manalthi, founder, president, and CEO, and Jared Golub, our chief medical officer. Following our prepared remarks, we'll open the call to questions from our publishing analysts. If you'd like to ask a question, please use the raised hand icon, which can be found at the bottom of your meeting window.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

And to help us move efficiently through the Q and A session, we ask that you're ready to unmute your line when called upon. Ask that you're through Before we begin, I'd like to remind you that today's discussion will include forward looking statements about our future expectations, plans and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10 Q filed with the SEC. Any forward looking statements speak only as of today's date, and we assume no obligation to update any forward looking statements made on today's call. With that, I'll turn the call over to Nello.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Thanks, Bruce, and thank you for joining us this morning. As I mentioned at the beginning of the year, we set ourselves up for a very productive and exciting 2025, and we're delivering on that promise. The updates we've shared in the first half of the year represent a powerful validation of Chimera's innovative and disciplined approach to drug development within the biopharma industry, while paving the way for our future progress across our high impact immunology pipeline. We're committed to leveraging the unique capabilities we have developed to unlock disease biology and deliver groundbreaking oral degrader medicines for areas not served well by existing technologies. Today's immunology treatment landscape still leaves millions of patients without adequate options, forcing difficult trade offs between efficacy, safety, cost, convenience.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Millions of patients with life altering immune inflammatory diseases don't have access to advanced systemic therapies, mostly injectable biologics. This is true if we look across countries with extremely diverse systems on how they prescribe, reimburse and deliver these highly effective medicines. The issue is really more fundamental than the inefficiencies of the health care ecosystems around the world. Simply put, well tolerated oral drugs that can be as effective as these difficult to access injectable biologics have the potential to transform the treatment landscape and in doing so, impact lives of millions of patients. This is what we're set to do at Chimera.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

It's an exciting time for the company, and I wanna take a moment to briefly recap some of the key accomplishments of the 2025. Starting with our first in class statics program, we completed the first KT six to one trial in healthy volunteers and reported positive results that exceeded even our high expectations, surpassing our target product profile. Importantly, the data further derisks our path forward and highlights the possibility of KT621's dupilumab in appeal profile. As potential first in class treatment, we believe KT621 has the ability to be a broadly accessible oral option for many dermatological and respiratory diseases like AD and asthma. In addition, for Japanese regulatory purposes, we recently completed a second small healthy volunteer study in Japanese subjects with results that were consistent with The US study.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

You can expect that we'll present these findings at a future medical meeting. We also wanted to share a few updates regarding KT-six 21 Phase Ib broaden study in moderate to severe AD patients. As noted in the release, the patients' data we plan to share will include data from two different dose groups. While we initially set out to explore a single dose, the speed at which the trial enrolled allow us to evaluate the translation from healthy volunteers into patients more broadly, which we believe gives us an even richer dataset to inform our phase 2b dose choices, which was an important goal of this study. The phase 1b was designed with a flexible protocol that contemplated this scenario, allowing us to make this choice without impacting timelines and as a result, we're well positioned to report results in the fourth quarter as planned.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

I'm also happy to share that we have selected and finalized the three doses that will be included in the two Phase 2b studies as well as completed long term toxicity studies. These were really the final important pieces of our planning to start these studies beginning later this year. Given we're moving into data collection and analysis mode soon, we're going to limit our comments around the study to what we have said previously until we're able to share the full results in the fourth quarter. But we can certainly say that we're pleased with the speed at which the trial has enrolled, very excited by the trajectory of the program and we look forward to sharing the full dataset when it's available. The additional PRISM news to share is that we have select a follow on STAT6 degrader to KT6:one with strong potency, selectivity and safety profile and have advanced it through all required IND enabling studies.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

The degrader is IND ready should we decide to further advance it into the clinic in the future. More broadly, we're building what we believe is the best in industry oral immunology pipeline. And beyond STAT6, we're also very excited about what's next. Early this year, we've unveiled our oral IRF5 program, which is moving through IND enabling studies. The compelling preclinical data we've generated showcases that targeting IRF5 can lead to correcting immune dysregulation across multiple disease pathologies while generally sparing normal cells.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And it remains our goal to progress our early discovery pipeline of novel immunology programs, unveiling one new program per year to expand access to oral systemic advanced therapies for broad patient populations in the space. We hope to share more about this next year. Additionally, we announced two important partnerships updates in June. First, we're very excited to announce our first oral molecular glue degrader program targeting CDK two will be developed under our collaboration agreement with Gilead. We have a highly innovative research engine and the CDK two program is a great example of this given the challenges of existing technologies to address this highly valued target.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

With our focus in immunology, this program was the ideal candidate for partnering. We and Gilead believe that a highly specific, safe and effective CDK2D grader has exciting potential to meaningfully improve treatment for patients living with breast cancer and other solid tumors that are inadequately treated today. Secondly, Sanofi announced that they officially opted in into the IRAK4 program and will assume full responsibility for development activities of KT485, our second generation oral IRAK4 degrader, which we expect to advance into Phase I testing next year. Based on our preclinical results, KT-four eighty five has greater potency, broader distribution and a generally improved overall profile than KT-four seventy four, our first generation degrader. As a result, Sanofi made the decision not to advance four seventy four into further development as KT-four eighty five has the greatest potential benefit for patients.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Both these collaborations have the potential to realize significant milestones for Chimera, which Bruce will cover later in the call, and we're happy to collaborate with two industry leaders on these novel programs. Finally, to support all we have ahead of us, we've extended our cash runway into the 2028. We raised approximately 288,000,000 in the follow on offering that we launched at the June and received the upfront payment from Gilead increasing our cash position to $1,000,000,000 as of the July. Our well capitalized balance sheet should allow us not only to take KT six to one through the planned phase 2b studies in AD and asthma, but also to prepare for and initiate several phase three studies across multiple indications while also progressing an earlier stage pipeline. As you've heard me say before, our strategy centers on combining the unique power of targeted protein degradation with carefully selected targets and pathways to create transformative new class of medicines.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

By focusing on immunology, we're not only addressing large patient populations, but also meeting a significant unmet need to create effective save oral therapies. We believe our approach has the potential to deliver for the first time in our industry biologics like efficacy with the ease and convenience of an oral pill. Again, I couldn't be more excited about the foundation we built and where we're going. I'm looking forward to the Q and A discussion, but let me pause here for Jared to discuss KT-six twenty one and our pipeline. Jared?

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

Thanks, Nelo.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

Looking back on the last quarter, we were excited to share the first KT-six twenty one clinical data, which we believe greatly derisks the next stage of development. We identified clear goals for the Phase I healthy volunteer study, and the data not only hit the mark, but in many instances exceeded our expectations with compelling translation from preclinical studies to humans. The primary objective in the healthy volunteer study was to show that we can robustly degrade STAT6 in blood and skin, which we define as a reduction of 90% or more at doses that are safe and well tolerated. As shown here, the results exceeded our expectations across every measure. We showed more than 95% degradation in both skin and blood at very low doses.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

The safety profile was undifferentiated from placebo. And we are encouraged by the biomarker profile, which we believe is at least comparable to what dupilumab showed in healthy volunteers or patients and, in some cases, is superior. That said, I'd like to take a few minutes this morning to recap the results and next steps with KT-six twenty one, which we believe has the potential to profoundly alter how PH2 diseases are treated by delivering an oral drug with a biologics like profile. For the full dataset, please reference the slides presented in early June, which are available on our website. As a reminder, we enrolled 118 volunteers in a randomized double blind placebo controlled study to assess single and multiple ascending doses of KT621 across a range of doses from six point two five to eight hundred milligrams in SAD and from one point five to two hundred milligrams in MAD.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

In all SAD cohorts, including the lowest dose of six point two five milligrams, KT621 degraded stat six by 90% or more, and at doses of seventy five milligrams or greater achieved complete degradation, with greater than 95% mean stat six reduction and stat six levels below the lower limit of quantitation in multiple subjects after just a single dose. In MAD, where volunteers were dosed daily over two weeks, we were able to completely degrade STAT6 in both blood and skin at doses of fifty milligrams and above. In fact, to establish the lower end of the dose response curve, we had to go back after the initial cohorts and add the one point five milligram MAD cohort, given none of the initially planned doses had less than 90% degradation. The robust degradation of STAT6 led to functional inhibition of the IL-fourthirteen pathway as demonstrated by median reductions of up to 37% for TARC and up to 63% for eotaxin-three at day fourteen, a result that was comparable or superior to what has been observed for dupilumab either in healthy volunteers or in patients with Th2 diseases. Importantly, whether treated at the lowest or highest dose or anywhere in between, the safety profile was undifferentiated from placebo.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

There were no serious adverse events, very few treatment related adverse events that were mild, no treatment related discontinuations, and no clinically relevant changes in vital signs, laboratory tests, or ECGs with daily dosing up to two hundred milligrams, which is 16 fold above the lowest MAD dose with greater than 90% degradation. As many of you have asked, we are also happy to share that we recently completed our four month GLP toxicology study. And consistent with our earlier non GLP and GLP tox studies, we did not see any adverse events of any type at all of the doses tested. This study completes the necessary preclinical work to allow us to initiate the Phase IIb trials planned to start later this year and early next. Prior to reporting the healthy volunteer data, we initiated a twenty eight day Phase Ib trial named BROADIN, which was designed to enroll approximately 20 moderate to severe atopic dermatitis patients.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

We've had a high level of engagement from sites on the trial and are pleased to report that we are on track to share data in the fourth quarter. As a reminder, the key study aim is to show that robust STAT6 degradation in blood and skin lesions by KT621 has a dupilumab like effect on multiple Th2 biomarkers in the blood, TARC being the most relevant in AD patients as well as on the Th2 transcriptome of active AD skin lesions. We will also assess KT621's effect on clinical endpoints, such as EASI and pruritus NRS. Beyond the phase 1b BROADEN study, which, again, is designed as a streamlined biomarker focused study, we are planning parallel phase 2b dose range finding trials to enable subsequent registrational phase three studies across multiple indications. As Nella mentioned, we have selected the three doses for the studies, and our Statistics team has done a remarkable job keeping this program moving at a rapid pace, including all the necessary work to initiate two global Phase IIb trials.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

The AD Phase IIb trial will begin in the fourth quarter this year, and the asthma study is expected to initiate in the 2026. And quickly on the IRAF5 program. Historically, an undrug transcription factor and genetically validated target, IRAF5 is a master regulator of innate and adaptive immune response pathways involving pro inflammatory cytokines, B cell activation and autoantibody production, and type one interferons. We believe IRA5 degradation has the potential to be the first broad anti inflammatory mechanism that effectively addresses immune dysregulation while sparing normal cell function. KT579, our potent selective and oral degrader, has the potential to be the first IRA5 targeted therapy to deliver a completely novel and potentially transformative treatment option, in many cases, superior to pathway biologics, in a range of autoimmune and rheumatic indications such as lupus, RA, Sjogren's, and others.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

This program is progressing in IND enabling studies, and we expect to advance KT579 into phase one testing in early twenty twenty six with what we believe will be the first oral IRA5 degrader to enter the clinic. Across our portfolio, we see strong potential to advance multiple first in class oral degraders that address major market opportunities in immunology. Our STAT6 and IRF5 programs represent significant advancements not only for our pipeline, but for the industry and patients as we look to deliver the first oral therapies with biologics like profiles in immunology. We're excited about their continued progress and remain focused on our goal of expanding access to transformative treatments for millions of patients. So let me pause here, and Bruce will review our second quarter financial results and provide a collaboration overview. Bruce?

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

Thanks, Jared. I will quickly run through our results for the quarter. Also, because this past quarter has been busy with collaboration and financing activity, I wanted to provide a brief summary of our recent news as well. As I walk through the second quarter results, please reference the tables found in today's press release and 10 Q, which was filed this morning. Revenue in the 2025 was $11,500,000 all of which was attributable to the Sanofi collaboration.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

With respect to operating expenses, R and D for the quarter was $78,400,000 Of that, approximately $8,000,000 represented noncash stock based compensation. The adjusted cash R and D spend of $70,400,000 which excludes that stock based comp, reflects a 3% decrease from the comparable amount in the 2025. On the G and A side, our spending for the quarter was $17,600,000 of which $7,400,000 was noncash stock based comp. The adjusted cash G and A spend of $10,200,000 again, excluding that stock based compensation, reflects a 6% increase from the comparable amount in the prior quarter. And overall, adjusted operating expenses in total were down slightly from the prior sequential quarter.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

We ended June with a cash balance of $963,000,000 Our quarter end cash balance included the base proceeds from our $250,000,000 follow on offering that closed at the June. The June total does not include either the additional proceeds from the underwriters' overlapment option, which was fully exercised in July, or the first payment that we received from Gilead as part of our recently signed CDK two partnership, both of which were received in July. As a result, we ended the month of July with a cash balance of approximately $1,000,000,000, providing a cash runway into the 2028. Just a quick reminder that our runway calculations exclude any unearned milestones. And with that in mind, I'd like to take you briefly through the key financial terms of our two collaboration agreements.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

Starting with Gilead, under the collaboration, we're eligible to receive up to 750,000,000 in total payments in addition to tiered royalties on net product sales that range from the high single digits to the mid teens. This 750,000,000 includes $85,000,000 related to the upfront payment, which was received in July, and you can see on our balance sheet shown as deferred revenue, and the potential option exercise. If Gilead chooses to exercise its option for an exclusive license, they will assume global rights to develop, manufacture, and commercialize all products arising from the collaboration. Turning to Sanofi and the development of KT-four eighty five, under the existing collaboration, we could earn up to $975,000,000 in clinical, regulatory, and commercial milestones for KT-four eighty five. We retain the right to opt in to a fifty fifty cost and profit share in The US prior to the first phase three trial in addition to international royalties.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

If we decide not to opt in, we would instead be entitled to worldwide royalties ranging from the low double digits up to the high teens. To conclude, as you've heard today, there's a great deal of momentum across our programs. And importantly, we have the resources in place to continue executing on our development strategy and the progression of our earlier stage pipeline. With that, we'll pause here so we can convene in our main conference room, at which point, we'll open the call to questions. Thank you.

Operator

Thank you. At this time, if you would like to ask a question, please click on the raise hand button, which can be found on the black bar at the bottom of your screen. If you have joined by phone, please dial 9 on your keypad to raise your hand. When it is your turn, you will receive a message on your screen inviting you to join as a panelist. Please accept and wait until you are promoted to panelist.

Operator

Please unmute your audio, turn on your camera, and ask your question. As a reminder, we are allowing analysts one question and one related follow-up today. We will now pause a moment to assemble the queue. First question is from Michael Schmidt from Guggenheim. Please unmute yourself and begin with your question.

Paul Jeng
Vice President at Guggenheim Partners

Hey, guys. It's Paul on for Michael. Thanks for taking our question. I had one on the dose levels, that you're exploring for six two one. Maybe first, could you provide some color on that decision to add the second dose in the phase one b study?

Paul Jeng
Vice President at Guggenheim Partners

I I think it's probably safe to assume that both the doses fall within the broad range that achieved complete statics degradation, but just wondering how you're thinking about exploring both the the high and the low dose versus perhaps two doses in the higher range.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. Thanks, Michael. Wanna make sure we're you can hear us. So so as we said today, so the doses both doses are within the range that we that we explore in the phase one anti volunteer study. And as we've also said, as you're aware, we had initially decided to explore one dose thinking that, you know, roughly 20 patients will will be enough to give us the data to speak to what is the profile of that one dose.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And then, obviously, as we were moving along with the enrollment and given how quickly it was going and, you know, given that we were able to assess the performance at one dose, we decided to explore an additional dose so that we'll get even robust translation from multi volunteer to patients of, you know, stat stat six degradation. I think it's important to keep in mind that in the healthy volunteer data, we had multiple doses. I would say almost all doses besides one met our target product profile. And so we wanted to confirm that the really, really robust profile could be translated into patients with the same level of fidelity. And so I think we're happy that we did that.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Obviously, I'm not gonna speak to high, low, medium, etcetera. Rest assured that the main goal was really to refine the phase two b dose selections. And so the the all that happened so quickly that now between the healthy volunteer data and whatever data we have access from this study, we're able to firm up and select the phase three the phase two b doses even in the absence of of completing the phase one b study.

Paul Jeng
Vice President at Guggenheim Partners

Great. And if I kind of quick quick follow-up on that that point, mostly on just what backed into the dose selection for the phase two studies. Was it predominantly the healthy volunteer data you presented? Was there anything emerging from the Japanese studies or GLP tox? Can you say if there's a different range of doses being explored between the AD and the asthma studies? Thank you.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. No. So a great question, actually. So as you saw, it was a very, very busy q two. I I don't think we've had a busier q two in the history of the company given everything that we've accomplished.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So I will say that if you look back at the healthy volunteer data, there was a dose selection based on this data. Everything else that we've done confirmed was able to confirm our initial instinct. We didn't learn, to be honest, anything new that made us change the initial instinct, let's say, on dose selection, but it was highly encouraging that everything that we'd seen in healthy volunteer was supported by, obviously, the four month talks, which we said was completely clean, the Japanese study, which was very much in line with The US study, and the early let's call it early data for the phase one b.

Paul Jeng
Vice President at Guggenheim Partners

Great. Thanks very much.

Operator

The next question is from Derek Ochilla at Wells Fargo. Please unmute yourself and begin with your question.

Derek Archila
Derek Archila
MD & Equity Research Analyst - Biotechnology at Wells Fargo

Hey. Good morning, and, thanks for taking the question. Congrats on the progress here. So just one and a follow-up. So, basically, just wanna understand maybe following up on this this line of questioning just in terms of what you would expect to see, you know, at these, at these additional doses that you're looking at in the phase two b.

Derek Archila
Derek Archila
MD & Equity Research Analyst - Biotechnology at Wells Fargo

Ultimately, like, we saw very good degradation and and and pretty quick. So I guess, you know, how do you think some of the doses will differentiate? And then just a follow-up to that, you know, what do you what do you actually expect to see with the follow on stat six that you're developing? What sort of optionality are you really looking for with that molecule? Thanks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Great question, Derek. So the first one, I just wanna confirm we're talking about the dose for the phase two d. So I think the important thing for a drug, obviously, is to find a a dose that is has the best risk reward profile. And so I think what we wanna ask in a, you know, in in a sixteen let's say, for AD, a sixteen week study is what is the maximal or we believe close to maximal at that point level of clinical activity that we would see, and what is the safety profile at different levels of degradation. Obviously, we will we'll explore maximal degradation, which we call complete, which, again, is where, really, we see in most subjects, stat six level be below the lower limit of quantitation.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So we wanna ask that question. What is the clinical profile of maximal degradation? And then, obviously, we wanna ask the question at a couple of lower doses just to, again, at the end of the study, being sure that we're taking into phase three the profile that we believe has the best risk reward. So it it's obviously a necessary step that we need to take as a company to fulfill regulatory requirements to do dose ranging study before selecting a phase three dose. You know, I think we have bets in the company on what that phase three dose would be already, but we gotta run the studies and make sure that we do all the right steps to derisk the program.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

With regards to the follow on molecule, so that's something many of you that has followed us for years know that every program, we always have a a next generation molecule. As you saw for IRAK four, Sanofi decided to focus the efforts on the full on, then we we call it the next generation molecule, k t four eight five. For for stat six, to be honest, we didn't really have a particular goal with the with the next generation compound given how well k t six two one has performed. And this is the reason why, you know, we've advanced a very good molecule that in many ways looks, at least in terms of profile, very much like k t six two one. It's, you know, potent, extremely well tolerated, very active in vivo.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And the principle is, you know, to to support the franchise for one is for the eventual, you know, unlikely scenario that we need another molecule or for a for a strategic choice of eventually advancing another molecule should we choose to do for different severities or different indications. I think given how well k d six two one is doing, we have decided for now to keep this full on molecule IND ready, meaning that we have everything we need to file an IND, but we're not planning to file an IND in the in the short term. I think another important point in this highly competitive space as statistics is becoming, having a molecule IND ready probably ahead of any other, let's call it, competitor that that is behind us. So we have two molecules ahead of every other competitor. I think he also sends a message how committed the company is to this franchise and to potential of this franchise.

Derek Archila
Derek Archila
MD & Equity Research Analyst - Biotechnology at Wells Fargo

Excellent. Thanks, Nelo.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Thanks, Eric.

Operator

Question is from Andrea Newkirk at Goldman. Please unmute yourself and begin with your question.

Andrea Newkirk
Andrea Newkirk
Biotechnolgy Equity Research at Goldman Sachs

Hi, guys. Good morning. Thanks for so much for taking the question. Two for me as well. Maybe the first, recognizing the primary objective of the phase one b data is to show a dupi like profile here on biomarkers.

Andrea Newkirk
Andrea Newkirk
Biotechnolgy Equity Research at Goldman Sachs

But I was hoping you might be willing to frame your expectations on what you'd like to see on the clinical efficacy measures, particularly EC75 as well as NRS. And then secondly, just noting the completion of the GLP talk studies that you mentioned, and obviously your phase one healthy volunteer also looked really clean. But, if you could just speak to the potential safety risks of degrading stat six completely, What type of signals are you most looking for in the phase one b to to really feel comfortable here with the safety profile, as you move forward? Thanks so much.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Well, thanks. Great question. Jared, I thought maybe you could take Sure. At least the first one, if not both.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

Yeah. In terms of on the on the clinical expectations, I think, you know, we've emphasized always that the primary objective here is to show robust stastic degradation in the blood and in active AD skin lesions and to show that that results in a dupial like biomarker effect both in blood and in skin, where in skin, we're looking at the t h two transcriptome and and the wanting to see a dupial like effect there. You know, we sort of have set our expectations around biomarkers. I think TARC is the most important blood biomarker probably in AD where, you know, Dupi studies have shown even at twenty eight days about a 70 plus percent reduction in dupilumab. So that's a general ballpark that we would expect to see in patients who, like in those Dupi AD studies, had greatly elevated TARC levels at baseline.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

We'll be looking at other biomarkers in the blood as well as these, you know, various, you know, transcriptional biomarkers in the skin. In terms of clinical endpoints, again, we've always emphasized that in the absence of a placebo control, these are more exploratory. However, we think we do have an opportunity to look at endpoints like EZ and pruritus NRS and IgA because we know from Dupi that you can see impact on those biomarkers as early as twenty eight days. And we're not really giving specific numbers where that bar would would be set. I think the published data are out there with Dupi, and one can look at those published data at twenty eight days and get a sense for what we mean by sort of being in the ballpark with regard to those clinical endpoints.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

In terms of your second question around safety risks, as you noted, you know, we've been very pleased with what we've seen in our GLP tox studies. We've now, you know, completed our four month tox studies as Noah indicated, and we've seen no safety signals whatsoever. That's very in line with our four week GLP tox and our prior non GLP tox studies. We're very encouraged by the fact that our safety profile was undifferentiated from placebo in healthy volunteers with two weeks of dosing, so that's very encouraging. And now we'll be looking at safety with four weeks of dosing, of course, in the in the phase one b.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

I think overall, this is in line with our expectations based on our mechanism of action and and based on the fact that it appears that, you know, stat six is highly selective, you know, for the IL four, IL 13 pathways in human genetics have pointed, you know, not just to the phenotype of abnormalities in stat six, but also to the safety of knocking down stat six as have mouse knockout studies. And so this is all in line with what we expected for a transcription factor that is very specific for IL four and IL 13 and for a drug like ours that is highly selective just for stat six.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

I would only thanks, Jared. I wouldn't say anything differently. I will only add one thing just to be clear. Again, as Jared said, on the clinical endpoints, it's difficult to compare you know, it's also difficult to compare placebo controlled randomized study. Like, the industry is full of these these arguments over comparing placebo controlled studies.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So it's even more difficult to compare noncontrol study. But but I just wanna say our expectations are that we will have a very active drug. I don't wanna hide behind impossibility to compare. We expect that this mechanism is gonna be in on par with what dupilumab has shown, and that's the bar for us without talking about numbers.

Andrea Newkirk
Andrea Newkirk
Biotechnolgy Equity Research at Goldman Sachs

Okay. Understood. Thanks, guys.

Operator

The next question is from Faisal Khershid at Leerink. Please unmute yourself and begin with your question.

Faisal Khurshid
Senior Research Analyst - Emerging Immunology at Leerink Partners

Hey. Good to see you guys. Thanks for taking the question. Just want to ask on the doses for the phase 1b and the phase 2b. Are you able to confirm if the dose that you added to the phase one b is higher or lower than the dose that you originally went in with?

Faisal Khurshid
Senior Research Analyst - Emerging Immunology at Leerink Partners

And could you also confirm if, like, either or both of these doses are part of, like, the three that you selected for phase two b?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So so so I I don't wanna get into the higher or lower because I think whatever I say is gonna be viewed one way or the other. What I can say is that both doses have been tested in the healthy volunteer studies. I don't wanna talk about what what our doses are for the two b because I think we might choose to keep that, as I've said, in other venues, to keep that close to the vest for as long as we can only for competitive reasons. All I can say that, you know, we have several doses in the healthy volunteers that performed really well. And so, really, the main driver here, are these doses going to perform as well in patients given that I actually don't remember the number.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Bruce will know better, but we're spending tens, if not 100 plus millions of dollars in these two studies. And we're not gonna optimize over you know, for these studies on, you know, making or thinking that we selected the right doses. These are consequential decisions. And so so given that we had the time to do it, we said, let's make sure. So that's really what's behind this.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And, you know, I think once we'll share the data, we can add a bit more color to what came first.

Faisal Khurshid
Senior Research Analyst - Emerging Immunology at Leerink Partners

Got it. Makes sense. And then could you confirm if it's still 20 patients for the phase one b? And then also, like, between the two doses, would you like to, or do you have to see a dose response between those two doses?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Great question. So I think what we said that that the the goal of the one b was approximately 20 patients, and that's still the case. I don't wanna get into the the dose response. I think we will talk about it once we once we share the data.

Faisal Khurshid
Senior Research Analyst - Emerging Immunology at Leerink Partners

Sounds good. Thanks for taking the questions.

Operator

The next question is from Alex Thompson at Stifel. Please unmute yourself and begin with your question.

Alex Thompson
Managing Director at Stifel Institutional

Hey. Good morning. Thanks for taking my question. I guess another question on the next gen STAT6. How different is the, scaffold, binding to STAT6 than six twenty one?

Alex Thompson
Managing Director at Stifel Institutional

Is that a key part of this decision making? And when might you consider potentially splitting indications here? Is that a near term decision, or are you gonna wait, quite a while before that, comes down? Thanks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. So what I can say thank that's a great question, Alex. So we have several scaffolds, let's call it, across actually all binding moieties, whether it's e three ligase or it's stat six. We have plenty of chemistry. Some, you know, patents have published from us.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

As many have seen, there is plenty that haven't yet. So we have a plethora of chemistry in this program that covers everything that you can imagine. So maybe I'll leave it at that. On the indication splitting, it it it it's a bit obviously challenging to to think about that particular endgame given kind of the evolving landscape right now in terms of pricing and reimbursement and global versus US. So I think we wanna keep maximal optionality, and that's kind of the goal behind everything that we're doing.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

But it's difficult for us right now to at least disclose what's the latest thinking on that. But, you know, as we get closer to phase three, which, you know, which actually with the the the recent raise, hopefully, was clear from from our remarks earlier. Now with the money we have in hand, we can actually initiate multiple phase three studies. So we I think as we get closer to those, we'll be able to disclose more about what our indication sequence and strategy would be.

Alex Thompson
Managing Director at Stifel Institutional

Great. Thank you.

Operator

The next question is from Tazeen Ahmad at Bank of America. Please unmute yourself and begin with your question.

Tazeen Ahmad
Tazeen Ahmad
MD - US Equity Research at Bank of America

Hi, guys. Good morning. Thanks for taking my question. Going back to the data that you're gonna have by year end, I just wanted to ask, you've talked about your expectations for what data you're going to show, should we assume that you're also gonna be able to show some level of itch data? I ask because some doctors have indicated that in addition to, let's say, EC scores, that is something that they feel is important when they're gonna make a decision in a real world setting about what potential options they might choose? Thanks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. Tazeen, yeah, it's a great question. And as Jared said, yes, we will show easy pruritus NRS, and so itch is gonna be an important factor. As you know, itch is probably has the biggest impact on quality of life of these patients, and so it's something that we're watching very closely. So we will share that data as well.

Tazeen Ahmad
Tazeen Ahmad
MD - US Equity Research at Bank of America

And will that be for all the patients that you're gonna show, or it'll be a subset?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Well, I mean, if we if we have collected the data, yes, so we will share it. So, yes, it should be all patients.

Tazeen Ahmad
Tazeen Ahmad
MD - US Equity Research at Bank of America

Okay. Thank you.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yep.

Operator

The next question is from Kelly Shee at Jefferies. Please unmute yourself and begin with your question.

Kelly Shi
Kelly Shi
SVP & Senior Research Analyst - Biotechnology at Jefferies

Congrats on quarter. So one question on status six. Conjunctivitis is believed to be on target a year for Dupixent. So do you expect to see similar level of conjunctivitis in k t six two one phase one b trial, like in one or two patients? And also, could a daily oral drug differentiate a safety profile versus of versus injectables due to a potential Limablat's PK curve? Thanks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Maybe I'll I'll start, and then I'll pass it to Jared that can speak more to the medical part. I mean, our view at Chimera is that stat six and and hopefully, it's not just here at Chimera. Stat six is the selected transcription factor of IL4 and 13, and we've shown preclinically, early clinically, and hopefully, we'll show in q four that if you block STAT6, you can phenocopy dupilumab. So if if conjunctivitis, which is actually mostly, if not only seen in atopic dermatitis patients, so it's really a a feature of the disease and decide for 13 biologics. So, again, if conjunctivitis is a on mechanism event adverse event for I four n 13 biology, then we expect to see.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

If it's to do with the receptor or the cytokines, then we wouldn't see it. So it's hard for us to know. Maybe, Jared, you can speak to you know, also, you know, is it seen after only four weeks? I don't know.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

Yeah. I mean, you know, mechanistically, you know, it's not really known why some patients, especially AD patients, do develop conjunctivitis. If you look at the dupilumab studies, when you do see conjunctivitis, oftentimes, you'll see it within the first, say, four to eight weeks or so of treatment, and then over time, it actually tends to diminish. You know, it is a an adverse event that one does see with Dupi. It's not a dose limiting adverse event, and most of the cases with dupi are sort of in the mild to moderate range.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

I think, importantly, you know, we haven't seen it preclinically in our tox studies. We haven't seen it in healthy volunteers, and we really wouldn't expect to see it there in healthy volunteers since this appears to be something unique to AD patients. But as Nello said, you know, we don't have any reason to believe that we'd see either less or more AD patients compared to what dupilumab has seen.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

But, yeah, we're we're watching it because it's a it's an interesting, obviously, feature of many of these drugs. Right? It's not only dupilumab, all the I thirteen drugs have it. So we're watching that very closely and see if we see it in our four week studies, and we'll obviously, we'll share all the data in four q. And then you talked about the safety difference between once oral daily and a and a biologics.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

I mean, from from what we have both understood and what we've empirically derived in our preclinical studies, dupilumab has a very, very robust pathway blockade. I would compare dupilumab pathway blockade pretty much in line with the level of pathway blockade we see from our fifty hundred mg dose, two hundred, you know, the the complete degradation type of pathway blockade. I would put it on that kind of level of pathway blockade. So if that's the case, then I don't see why pathway blockade coming from stat six degradation should look different from pathway blockade from an alpha alpha blockade. So, anyway, I think that's another feature and another part of the analysis that we will do.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Again, I'll repeat, in our preclinical study now where I did the four month talks, k t six to one has been exceptionally well tolerated, so we'll continue to, again, watch everything that happens in the clinic.

Kelly Shi
Kelly Shi
SVP & Senior Research Analyst - Biotechnology at Jefferies

Super helpful. Thanks.

Operator

Question is from Judah Frommer at Morgan Stanley. Please unmute yourself and begin with your question.

Judah Frommer
Judah Frommer
Executive Director - Senior Equity Research Analyst at Morgan Stanley

Yeah. Hi, guys. Thanks for taking the question. Just one for us. I guess, can you comment a little bit further on enrollment progress and the success you're having there?

Judah Frommer
Judah Frommer
Executive Director - Senior Equity Research Analyst at Morgan Stanley

Maybe what feedback is from investigators? Is the oral administration of the drug resonating? And curious if you think you'd have similar success if there were a placebo arm in a trial.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yes. It's a great question. So the the challenge of a twenty eight day study, remember, is that the patients, you know, are are not gonna be on the drug beyond day twenty eight. We don't have an extension arm to the study.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So it's it's, I would say, before we started the study, we were nervous because, you know, the there there there aren't huge amount of incentives for patients to come onto the study besides knowing they'll be on an on an active drug. And that's part of the reason why we decided not to have placebo. We thought it would have had an impact on our enrollment rate. As we expect part of us or our expectation was that patients do want an oral drug, and so I think we are seeing that in our in our study. And the data has allowed us to, you know, meet our enrollment goal, I would say, even exceed our enrollment role for sure.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And maybe that's where I'm gonna leave it. I think once we start seeing more differentiation, it's probably gonna be in the phase two b study where now you're offering sixteen week potentially OLE. And so that would be interesting to see our enrollment versus biologics and whether it's telling us also something about what patients are also looking for in the market.

Judah Frommer
Judah Frommer
Executive Director - Senior Equity Research Analyst at Morgan Stanley

Right. Thanks.

Operator

The next question is from Kripa Devarakonda at Truist. Please unmute yourself and begin with your question.

Kripa Devarakonda
Kripa Devarakonda
VP - Biotechnology Equity Research at Truist Securities

Hey, guys. Thank you so much for, taking my question, and congrats on the progress through the quarter. So I'll ask one, nonstatistics question. So, congrats on your, CDK partnership with Gilead. I know this diversifies your pipeline into oncology where you've been focused a little bit more on INI in the recent past.

Kripa Devarakonda
Kripa Devarakonda
VP - Biotechnology Equity Research at Truist Securities

But given the data we've seen so far with CDK two inhibitors, can you talk a little bit about how you think the degrader could be differentiated based on the data that you have and what the strategy of development is? And then I have a follow-up.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. Yes. Thank you. So to just to be clear, our discovery engine has has been, you know, also very focused on immunology. We have programs that we were working on from the earlier days, and one of our program was in CDK two.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And so with our strategy shift to focus on developing immunology drug, we decided that it was best to place a very exciting CDK two program from a development step standpoint in the hand of a partner that was committed to that space. So that's a bit to the strategy. The reason why we have that program is because we firmly believe that small molecule inhibitors of CDK two are really not able to selectively target CDK two. They all inhibit to a large extent CDK one at pharmacologically active doses to different degrees. And that it leads to clinical doses that are probably not optimally blocking CDK two, again, for the risk of hitting CDK one.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Another important aspect for us to develop this drug was to have a brain penetrant asset so that we would also address potential brain secondary tumor or metastasis from breast cancer. And so our degraded program molecular to degraded program is highly specific CDK two also reaches the CNS. And we believe it's gonna has the potential to be best in class. If I look at the small molecules out there, it's by far superior. Obviously, I'm not aware of other programs that are in, you know, early discovery, early development, so I can say, obviously, for sure.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

But with regards to the development, that's a question you have to ask, Gilead. We, you know, we can't speak for them on that particular front.

Kripa Devarakonda
Kripa Devarakonda
VP - Biotechnology Equity Research at Truist Securities

Okay. Thank you so much. And just following up on Tazeen's question about itch relief, and this is something that we've heard from KOLs too that it's really important to see rapid re itch relief. Will we get a sense of that when we see the data, the rapidity of response in fourth quarter?

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

Yeah. We will. I mean, you know, as Nelo already mentioned, you know, looking at it pruritus NRS is is a key part of the sort of suite of clinical endpoints, and we'll be looking at it, you know, fairly regularly as we'll be looking at EASI. So we'll have a a good sense of the kinetics of impact on itch as well as on EASI. That will be sort of part of the profile that that we share once we have those data in q four.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. I think you you'll see, hopefully, that will be the case. But it would be like you know, we'll show day seven, day 14, then 21, day 28. So you'll be able to see the kinetics of all of these parameters.

Kripa Devarakonda
Kripa Devarakonda
VP - Biotechnology Equity Research at Truist Securities

Okay. Great. Thank you so much.

Operator

To note, each questioner can ask one question now. No follow-up questions. The next question is from Mayank Mantani at B. Riley. Please unmute yourself and begin with your question.

Mayank Mamtani
Senior MD & Group Head - Healthcare at B. Riley Securities

Yes. Good morning. Thanks for taking our questions, and congrats on the progress team. Any color you're able to provide on the baseline EZ scores of the patients you're enrolling or have enrolled. And and I wonder always about the screen failure rate for the topic dump trial sites.

Mayank Mamtani
Senior MD & Group Head - Healthcare at B. Riley Securities

And maybe just remind us how you're measuring degradation in skin tissues. There's obviously a, you know, a couple of ways to do that. And, lastly, any anything you've learned on the degradation from the four months GLP talks studies you completed?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Oh, yes. Four questions in there. So that's a way to

Mayank Mamtani
Senior MD & Group Head - Healthcare at B. Riley Securities

keep I will not ask a follow-up. I promise. No follow-up.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Well, you've asked four.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

My call.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Let's see if I remember. So the first one was the easy yeah. We're not gonna comment on the baseline easy, but I will refer you to entry. So the the baseline criteria for entering the study is easy above sixteen sixteen or above. There is obviously itch as well.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

There is PSA more than 10%. So we have strict criteria that really overlap with what has been done with dupilumab. On the, again, on the failure rate, again, Waltman, I don't know if we'll speak when we release the data. All I can say is that our team is watching the study very closely, and we we we've worked very, very hard to make sure that patients that enter enter our study actually have atopic dermatitis, which would be shock that that that, you know, could be possible if you don't watch the study closely that, you know, their their their disease is active. And, obviously, that their lab work is, you know, in line with making sure we're not, you know, taking sick patients on our study.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

So I think when you take all of that, that results into, obviously, screen failures that, again, I'm not able to comment on today. On the degradation in the skin, as we've done in many of our studies, we are fortunate enough to have patients on our study be willing to take biopsies, which, as you know, it does add an additional layer. That's why we're so impressed on how we were able to enroll patients again quickly because we asked patients to undergo biopsy at baseline and day 28 to to to measure stat six with the mass spec. So that's how we're gonna measure it.

Mayank Mamtani
Senior MD & Group Head - Healthcare at B. Riley Securities

Anything you learned from the GLP talk study on degradation?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

I mean, I mean, all we learn in these studies is that we obviously, at this tox doses, there is no stat six anywhere to be found even though we degraded completely. That's maybe all I can say. Yeah. If the question is, does this stat six degradation wanes off after sometimes? Obviously, the answer is no.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

We we see stat six degradation both throughout the study.

Mayank Mamtani
Senior MD & Group Head - Healthcare at B. Riley Securities

It's great to hear. Thank you.

Operator

The next question is from Jeet McCary at BTIG. Please unmute yourself and begin with the question.

Jeet Mukherjee
VP & Biotechnology Analyst at BTIG

Great. Thanks for taking my question. I know we're a long ways out, but can you speak to payer willingness to cover therapies in the dermatology space that give an alternative administration format, like an oral option with Dupixent like efficacy for k t six two one, or is there bar truly superior efficacy versus standard of care options? Thank you.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Well, no, it's a great question. We believe that when you make the case for an oral option, first, you will hear from prescribers that actually you don't even need to have dupilumab like activity for expecting a substantial adoption in the market. It just speaks to the fact that there is a need of flexible, easy to prescribe, reimburse, and take medicines. So the reason why we say dupil like in the pill is because all the data we've seen so far speaks to that. And so that's why our bar has always been there, hopefully, will continue to be there.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Again, I think when you make the case for head having a therapy even even with the same activity, you're telling actually insurance companies and prescribers and patients that that this drug has a much bigger impact on their quality of life and asking for a lot less, right, in terms of visit to the doctors, testing, you know, needing or lack thereof of, you know, cold storage of the drug, needles, injection site reactions. So I think that's the the value case that, you know, a a drug like this will have. And especially if you compare it to for example, the the only drug that right now is approved in AD, it's a drug with a black box, and that drug actually is doing quite well. I think that speaks and then it's a drug that requires testing before you start that therapy. And so it speaks to the hunger that that this market has for an oral drug.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And I think we you've seen in all in all markets, oral drugs and multiple effective therapies are needed to expand access and penetration. Now, you know, the especially atopic dermatitis market is really dominated by a single player, I would say, mostly with dupilumab, but it still has less than fifteen percent penetration. I would say if you look at all moderate to severe, it's less than ten percent. And so I think we need this option to expand access dramatically in The US and all over the world.

Jeet Mukherjee
VP & Biotechnology Analyst at BTIG

Appreciate it. Thanks, guys.

Operator

The next question is from Jeff Jones at OpCo. Please unmute yourself and begin with your question.

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

Good morning, guys, and thanks for taking the question. One question from us on Iraq four. Can you provide any additional detail behind what drove the exchange of $4.07 4 for the $4.08 5 candidate? You know, given the specificity differences, was there something that was being seen with four seven four that was concerning?

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Great question, Jeff. Thanks for asking about this. So just to remind everybody, the the decision was made by Sanofi to focus all the resources of the Eric for collaboration on k t four eight five. Based on preclinical data, k t four eight five seems to be superior to four seven four on both potency distribution, and we demonstrated also lack, complete lack of the subclinical QT finding that we had seen with four seven four in our clinical studies. I will also reiterate that that particular finding was self resolving with continued dosing, meaning that it will go away as you continue to dose.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And we didn't learn anything even in the ongoing phase two studies that that spoke negatively with regards to the safety of the drug beyond what we'd already shared. So I think it was really focused on the fact that four eight five overall seem to have a better profile, and and we believe both clinically and maybe commercially more competitive. And since you asked me about, actually, IRAK four, I thought it it's it's also interesting to see how the landscape is evolving. I don't know if if you guys have seen AstraZeneca starting about to start a big phase two study in in COPD after they've run a small earlier study, which we haven't seen data for, but they've they've shared that they're gonna share their data for their IRAK four inhibitor in HIT COPD. So that's it.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And that's another indication that we at Chimera thought IRAK four could be well positioned for. So it's exciting that a big company is I think it's a 400 patients. No. It's more than that. Yeah.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

A thousand patient study. So, anyway, just the field continues to learn and evolve, and, you know, we're excited to have a great asset out there that hopefully could also go towards that that direction. But that's something that we need to obviously discuss with Sanofi.

Operator

The next question is from Andy Chen at Wolfe Research. Please unmute yourself and begin with your question.

Andy Chen
Director, Senior Equity Research Analyst at Wolfe Research

Hey. Thank you for taking the question. On IRF five, is there a reason for degradation and cytokine reduction and all that to not translate into humans? It it looks like your stat six degrader has more than translated. Wouldn't all of that read through to IRF five, or is there still something special about that molecule that makes you think that, you're still maybe semi concerned and maybe the derisking steps are still ahead of you?

Andy Chen
Director, Senior Equity Research Analyst at Wolfe Research

And, also, what are the, top two, three, safety signals that you'll be watching for in humans? Thank you.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. Great question. So for IRAF five, I mean, we're the stage, to be honest, we've been here for a while, where all of our programs have translated really well. You can argue whether you like the the target and the biology translate, but all of our programs have translated really well in the clinic. So we expect IRAD five to translate just as well as k d six to one.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Also, for IRAD five, k d five seven nine in non GLP tox, we've seen no adverse event of any type, and we went up to 200 fold above the the expected 90% degradation human exposure. We are in the midst of IND enabling studies. I'm confident we'll continue to see an exceptionally well tolerated drug. So we're excited about that drug. We're working already really hard not only to prepare for the healthy volunteer study that would start early next year, but the team has been spending the past few months working on and planning our patient study that will will start soon after the healthy volunteer study.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

We're prioritizing indications. We're talking to KOLs and refining protocols. So, yeah, we we're working under the assumption that the translation will be, you know, happening just as well as it did for six to one.

Andy Chen
Director, Senior Equity Research Analyst at Wolfe Research

Thank you,

Bruce Jacobs
Bruce Jacobs
CFO at Kymera Therapeutics

Adam. We're just about up up against time. Operator, we'll try to just move really quickly through these last few.

Operator

One moment while we wait for questioners.

Jared Gollob
Jared Gollob
Chief Medical Officer at Kymera Therapeutics

The

Operator

next question is from Ellie Mel at UBS. Please unmute yourself and begin with your question.

Ellie Merle
Ellie Merle
ED - Biotech Equity Research at UBS Group

Hey, guys. Thanks so much for taking the question. Just another one on IRAK4. I guess, can you elaborate a little bit on what was seen clinically with the first generation IRAK4? And I guess, what gives you the confidence in the efficacy of this target in AD and HS?

Ellie Merle
Ellie Merle
ED - Biotech Equity Research at UBS Group

And, I mean, I heard your comments on, AstraZeneca. I mean, difference now in terms of how you might be thinking about the opportunity set across indications now for IRAK4? And then also just follow-up on CDK two. Can you elaborate on some of the learnings on working with molecular glues versus heterobifunctional degraders and your confidence in the selectivity for CDK two with these programs? Thanks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Yeah. So on on ERAK four quickly, we can't speak to what we've seen or not seen in the in these studies. Unfortunately, that is, you know, Sanofi's guidance on that. On the indications, again, this is, again, another question for Sanofi, but asthma and COPD have always been on the high priority list for for that biology. Obviously, we're talking about eosinophilic at COPD, which is a huge patient population.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

And with CDK two so we we again, we've historically said that these two, the heterobifunctional degree of molecular are two complementary technology, and they're not one, the next generation of the other. Although many companies seem to go in that direction. We use molecular glues where we believe that binding site and bind ability to bind to the target is either not feasible or not with the selectivity. If you use binding specific binding to CDK two, it's really difficult to find selectivity against CDK one, and that's why we built our CDK two degrader, which does not has any any kind of cross binding with CDK one. That's how we that's why we went in that direction.

Ellie Merle
Ellie Merle
ED - Biotech Equity Research at UBS Group

Great. Thanks.

Operator

There are no more questions at this time. I would now like to turn the call over to Nello Menalofy for closing remarks.

Nello Mainolfi
Nello Mainolfi
Founder, President, CEO & Director at Kymera Therapeutics

Well, thanks, everybody. Sorry we went a bit too long today. Another exciting quarter. We're here for any follow-up questions. You know where to find us, and thanks again for joining. Have a great day.

Executives
Analysts
    • Paul Jeng
      Vice President at Guggenheim Partners
    • Derek Archila
      MD & Equity Research Analyst - Biotechnology at Wells Fargo
    • Andrea Newkirk
      Biotechnolgy Equity Research at Goldman Sachs
    • Faisal Khurshid
      Senior Research Analyst - Emerging Immunology at Leerink Partners
    • Alex Thompson
      Managing Director at Stifel Institutional
    • Tazeen Ahmad
      MD - US Equity Research at Bank of America
    • Kelly Shi
      SVP & Senior Research Analyst - Biotechnology at Jefferies
    • Judah Frommer
      Executive Director - Senior Equity Research Analyst at Morgan Stanley
    • Kripa Devarakonda
      VP - Biotechnology Equity Research at Truist Securities
    • Mayank Mamtani
      Senior MD & Group Head - Healthcare at B. Riley Securities
    • Jeet Mukherjee
      VP & Biotechnology Analyst at BTIG
    • Andy Chen
      Director, Senior Equity Research Analyst at Wolfe Research
    • Ellie Merle
      ED - Biotech Equity Research at UBS Group
Powered by Quartr